Aclarion's Nociscan Technology Begins Evaluation in LIFEHAB Trial for Chronic Low Back Pain

Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnosis, has announced the commencement of Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. This marks a significant milestone in the study of biomarkers associated with chronic low back pain and their potential role in determining optimal treatment strategies.

The LIFEHAB Trial is a randomized controlled study comparing outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation for patients suffering from chronic low back pain. The trial, which began enrolling patients in the second quarter of 2024, aims to include 202 participants who have experienced low back pain for more than one year.

Nociscan, Aclarion's proprietary technology, utilizes magnetic resonance spectroscopy (MRS) to identify biomarkers in the lumbar spine. The inclusion of Nociscan in the LIFEHAB Trial underscores its potential to aid physicians in determining which discs to treat and possibly predicting the most effective treatment options for individual patients.

Brent Ness, CEO of Aclarion, expressed enthusiasm about the trial's progress, stating, "We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play." He also noted the growing adoption of Nociscan in the research market, highlighting its potential as an early indicator of the technology's value.

The use of Nociscan in clinical research extends beyond the LIFEHAB Trial. Aclarion is currently awaiting results from a completed trial in Rome, where Nociscan was used to evaluate regenerative technologies. Additionally, two studies funded by the National Institutes of Health (NIH) are investigating Nociscan's role in treating chronic low back pain.

Ryan Bond, Chief Strategy Officer of Aclarion, emphasized the accelerating pace of Nociscan's adoption in the research market. He anticipates announcing more partnerships as the company works towards establishing Nociscan as the gold standard for determining which discs to treat in low back pain research protocols.

The LIFEHAB Trial's results, combined with other ongoing studies, could play a crucial role in achieving successful reimbursement for Nociscan in single-payer national health insurance systems, such as Norway's. This potential for widespread adoption could significantly impact the diagnosis and treatment of chronic low back pain on a global scale.

As chronic low back pain continues to be a prevalent health issue affecting millions worldwide, the development and validation of technologies like Nociscan represent important steps toward improving patient outcomes and reducing healthcare costs. The ability to non-invasively identify painful discs and predict treatment responses could revolutionize the approach to managing this common and often debilitating condition.

For more information on the LIFEHAB Trial, interested parties can visit https://classic.clinicaltrials.gov/ct2/show/NCT06169488.

As Aclarion continues to expand its presence in both clinical and research settings, the healthcare industry will be watching closely to see how Nociscan technology may shape the future of chronic low back pain management.